Articles

Poll

Podcasts

Slideshows

Videos

Stay updated with the latest healthcare breakthroughs, including FDA news and phase 3 trial readouts, in this week's essential news roundup.

The HCPFive: Top News for Healthcare Providers from the Week of 12/14

Al-Samkari discusses a potentially novel use for bevacizumab in improving outcomes for patients with lesions from non-HHT etiologies.

Systemic Bevacizumab Improves Chronic Bleeding from GI Lesions, With Hanny Al-Samkari, MD

Grifols’ fibrinogen concentrate is now approved for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency.

FDA Approves Fibrinogen, Human-chmt (Fesilty) for Congenital Fibrinogen Deficiency

Al-Samkari discusses the slew of HHT-related complications, their frequency, and their severity, highlighting the need for more active intervention.

Patients with HHT Exhibit More Severe Complications Than Previously Believed, With Hanny Al-Samkari, MD

Zorrilla discusses the safety and efficacy of a series of minor surgeries in patients with hemophilia A/B currently taking fitusiran to control AT levels.

Minor Surgeries Safe to Perform in Patients Receiving Fitusiran Prophylaxis, With Julian Zorrilla, DO

Sohail discusses the promising results from this retrospective cohort study which aims to put longstanding concerns about worsening infection to bed.

IV Iron Reduces Mortality Risk in Iron Deficiency Anemia Without Increasing Infection Severity, With Haris Sohail, MBBS

Malec discusses the XTEND-ed trial, which proved the efficacy and tolerability of efanesoctocog alfa in adults and children with hemophilia A.

Efanesoctocog Alfa Improves Bleeding Regardless of Age in Hemophilia A, With Lynn Malec, MD, MSc

Pustake highlights the reticence with which clinicians should approach providing platelet transfusion to patients.

Platelet Transfusion Raises Mortality Risk in Consumptive Thrombocytopenia, with Manas Pustake, MD

FibroGen’s oral HIF-PH inhibitor showed improved transfusion independence in high–high-transfusion-burden MDS patients in a post hoc phase 3 MATTERHORN analysis.

FDA Grants Orphan Drug Designation to Roxadustat for Myelodysplastic Syndromes

Kuter discusses the efficacy and safety of rilzabrutinib in sustaining platelet responses and symptom improvement over the LUNA3 long-term extension.

Rilzabrutinib Preserves Platelet Response in ITP Through Extension Study, With David Kuter, MD

Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria Condition Center page, visitors can find resources on the topics of medical news and expert insight into PNH. Content includes articles, interviews, videos, podcasts, and breaking news on PNH research, treatment, and drug development.

Anemia

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Hematology